Das Klinikum

PD Dr. rer. nat. Melanie Märklin

E-Mail-Adresse: melanie.maerklin@med.uni-tuebingen.de

Immunosurveillance and immune evasion of tumor cells & NFAT signaling in lymphocytes and tumor cells

Deutsche Forschungsgemeinschaft: The role of NFAT2 for susceptibility of tumor cells to NK cell mediated antibody dependent cellular cytotoxicity
Deutsche Krebshilfe: Manipulating cytotoxic potential for NK cell-based immunotherapy
ImmuneMPS: Next generation microphysiological in vitro models of human immune responses in oncology
ENDO-RELIEF: Researching Endometriotic Lesions’ Interactions with the microenvironment to Explore pathogenic Factors

Seit 2022

Research Group Leader, Universitätsklinikum Tübingen, KKE Translationale Immunologie
Seit 2022

Privatdozentin (Habilitation), Medizinische Fakultät Tübingen
2022

Visiting Scientist, Mount Sinai, Precision Immunology Institute
2019-2022

Junior Research Group Leader, Universitätsklinikum Tübingen, KKE Translationale Immunologie
Seit 2016

Laborleitung, Universitätsklinikum Tübingen, KKE Translationale Immunologie, Prof. Helmut Salih
2015-2016

PostDoc, Universitätsklinikum Tübingen, Innere Medizin II, PD Dr. Dr Martin Müller
2010-2015

PhD, Universitätsklinikum Tübingen, Innere Medizin II, PD Dr. Dr Martin Müller
2005-2010

Diplom, Studium der Biologie, Eberhard Karls Universität Tübingen

Märklin et al., NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia, Nat Commun. 2017 Oct
Märklin et al., Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia, J Immunother Cancer. 2019 May
Publikationen